Pyrotinib inhibits tumor cell growth by blocking the formation of homodimers and heterodimers of EGFR and HER2 in tumor cells, inhibiting their phosphorylation, and blocking the activation of downstream signaling pathways (9). Here, ERBB2 is linked to neoplasm.